The “off-the-shelf” approach to gene editing CAR T-cells to treat cancer

Cellectis has pioneered the “off-the-shelf” approach to gene editing CAR T-cells to treat cancer and other genetic diseases. Dr. André Choulika discusses how this approach allows treatments to be produced by the thousands from healthy donor cells (versus the patient’s own cells), stored long-term, provided to hospitals around the world and given to any patient who is in medical need. Off-the-shelf gene editing marks the next transformative step in medicine, and Cellectis has the first U.S. clinical trials underway now.

Read More

The importance of bone health

The spotlight this month is firmly on bone health for healthcare practitioners. Osteoporosis is a common disease affecting over 1 million Australians. (1) Building and maintaining bone health is not something to only consider for older patients. Bone mass begins to decline at 35 years of age. (2) Building on the ‘bone bank’ is important for optimal long-term bone health and as we age it becomes critical in addressing bone mass loss. (3)

Read More